The abstract is read at the publisher; the summary is JClub's.
A CD19/HIV dual CAR T strategy in a humanized mouse leukemia model eradicated tumors comparable to CD19-only CAR T, while a CD19.BBζ-IL-18 plus CD4.28ζ-C34-CXCR4* design enhanced HIV and tumor control.
- Why it matters: Durable HIV control is difficult because viral rebound can occur, and CART approaches for B cell malignancies may not maintain HIV-specific activity over time.
- What they did: The team engineered IL-18 secreting CD19 CARs co-expressing an HIV-specific CAR plus the signaling-deficient C34-CXCR4 fusion inhibitor (C34-CXCR4*), then tested single versus dual CAR function and compared outcomes in humanized mice with CD4 T cells from a person with HIV.
- The result: Dual CAR T cells maintained antitumor efficacy comparable to CD19-only CARTs, and the CD19.BBζ-IL-18/CD4.28ζ-C34-CXCR4* combination showed enhanced T cell expansion and persistence with superior HIV and tumor control, supporting durable HIV remission potential.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.